1. Introduction
===============

Sudden sensorineural hearing loss (SSNHL) is common and is characterized by acute idiopathic hearing loss ≥20 dB at ≥2 continuous frequencies within 72 hours.^\[[@R1]\]^ SSNHL is often unilateral, accompanied by tinnitus, vertigo, and a sense of ear fullness. The incidence varies geographically; the condition is much more common than reported because spontaneous recovery in the absence of treatment is common.^\[[@R2],[@R3]\]^ Although the etiologies of most cases of SSNHL remain unknown, various pathologies may underlie SSNHL, differing in terms of the audiographic features. The Chinese guidelines for the diagnosis and treatment of sudden deafness (2015) and the German guidelines for the diagnosis of sudden idiopathic SSNHL (2004) stress that membranous labyrinthine edema may contribute to low-frequency SSNHL (LF-SSNHL); hair cell damage may trigger high-frequency SSNHL (HF-SSNHL); endothelial dysfunction or vasospasm can cause all-frequency SSNHL (AF-SSNHL); and an inner ear embolism or a thrombosis may play an important role in the pathophysiology of total-deafness SSNHL (TD-SSNHL).^\[[@R1],[@R4]\]^ Therefore, audiographic data are important when planning the treatment of SSNHL.

Blood examinations are simple and inexpensive, yielding information on red and white blood cell and platelet counts, the cell subgroups present,^\[[@R5]\]^ blood coagulation, inflammation, thrombosis, and atherosclerosis.^\[[@R6]\]^ Recent studies have focused on the associations of these variables with middle-ear inflammation and microvascular embolisms^\[[@R7]\]^; many reports have described associations between blood routine data including the count of platelet and lymphocyte, the mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), on the one hand, and SSNHL diagnosis and prognosis, on the other.^\[[@R3],[@R8]--[@R15]\]^ However, no work has yet explored the relationships of the count of platelet and lymphocyte, MPV, and PLR with SSNHL in patients differing audiographically. Thus, we evaluated the utility of these data in terms of SSNHL diagnosis and prognosis in such patients. Platelet is an important member of clotting system, lower lymphocyte is always associated with virus infection, PLR is a marker of inflammation, and MPV is a marker of atherothrombosis. We thus evaluated the roles played by inflammation and atherothrombosis in SSNHL patients who differed audiographically.

2. Materials and methods
========================

A total of 129 patients with SSNHL diagnosed at the Affiliated Sixth People\'s Hospital of Shanghai Jiao tong University were retrospectively enrolled. The patients were divided into 4 groups in terms of the pretreatment audiographic features defined in the Chinese guidelines for the diagnosis and treatment of sudden deafness (2015).^\[[@R1]\]^ The LF-SSNHL group contained 37 patients with hearing loss at 0.125 to 1 kHz or HL ≥20 dB at both 0.25 and 0.5 kHz. The HF-SSNHL group contained 28 patients with high frequency hearing loss at 2 to 8 kHz or at both 4 and 8 kHz (≥20 dB). The AF-SSNHL group contained 32 patients with overall hearing loss at all frequencies and mean pure-tone thresholds ≤80 dB from 0.25 to 8 kHz. The TD-SSNHL group contained 32 totally deaf patients (hearing loss at all frequencies and a mean pure tone threshold ≥81 dB from 0.25 to 8 kHz). The control group contained 31 age- and sex-matched healthy individuals without disease evident on regular check-ups.

Patients with any history of otological surgery, otitis media, trauma, acute or chronic inflammation, hypertension, diabetes mellitus, metabolic syndrome, heart failure, myocardial infarction, a cerebral embolism, cancer, hepatitis, nephritis, an autoimmune disease, chronic obstructive pulmonary disease, Meniere disease, infection of the upper respiratory tract, pregnancy, cor pulmonale, or for whom data were incomplete were excluded. All enrolled patients were treated within 7 days from disease onset, had received no previous therapy, and underwent both hematological assessment and pure-tone hearing testing during the first visit.

Audiometric examinations were performed in soundproof rooms to obtain the pure-tone thresholds for both air and bone conduction at 0.125, 0.25, 0.5, 1, 2, 4, and 8 kHz. A qualified audiologist performed the testing before treatment, 3 days, 1 week, and 1 month after therapy. Fasting blood samples were obtained before treatment to ensure that steroids would not be prescribed for high-risk patients with metabolic and/or cardio-cerebrovascular disease; all samples were drawn from the antecubital vein in the morning.

All patients were prescribed dexamethasone 10 mg/day (5 mg/mL, Furuitang Drug Industry, China) through intravenous for the first 3 days, then a progressively reductive dose was maintained for at least 1 week; vasodilators (Breviscapine injection, 40 mg/day, Kunming Longjin Pharmaceutical Co, Ltd, China) was injected for 2 weeks; oral neurotrophic factor (Extract of Ginkgo Biloba Leaves Tablets, 80 mg, tid, Dr Willmar Schwabe) was given for 1 month; and hyperbaric oxygen therapy if necessary for some patients. We evaluated treatment outcomes after 1 month therapy by reference to the Chinese guidelines for the diagnosis and treatment of sudden deafness (2015)^\[[@R1]\]^: complete recovery, the pure-tone thresholds of the impaired frequencies reached those of the normal unaffected ear; notable recovery, the pure-tone thresholds of the impaired frequencies improved by ≥30 dB; partial recovery, the pure-tone thresholds of the impaired frequencies improved by ≥15 dB but \<30 dB; and no improvement, the pure-tone thresholds of impaired frequencies improved by \<15 dB.

2.1. Statistical analysis
-------------------------

SPSS for Windows software, version 20.0, was used for all data analyses. Student independent-sample *t* test and ANOVA were employed to evaluate the significance of differences in continuous variables that were normally distributed. The χ^2^ test was used to compare categorical variables. Bonferroni and LSD post hoc test was applied to explore relationships between hematological parameters and audiographic shapes when the variances were homogeneous; Dunnett post hoc test was employed when the variances were not homogeneous. A *P* value \<.05 was considered to reflect statistical significance. GraphPad Prism version 6.0 for Windows was used to draw the figures.

3. Results
==========

We respectively analyzed the demographic characteristics and laboratory parameters of all groups (Table [1](#T1){ref-type="table"}). Neither age nor sex differed between the groups (both *P* \> .05).

###### 

Demographic and laboratory data.
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3.1. The platelet, lymphocyte count, MPV and PLR
------------------------------------------------

Figure [1](#F1){ref-type="fig"} shows that the platelet count was 218.35 ± 42.65 × 10^9^/L, 214.32 ± 63.07 × 10^9^/L, 224.59 ± 64.41 × 10^9^/L, 212.44 ± 45.11 × 10^9^/L, and 202.48 ± 46.61 × 10^9^/L in the LF-SSNHL, HF-SSNHL, AF-SSNHL, TD-SSNHL, and control groups, respectively. There was no significant difference between each study group and control group in terms of platelet count (*P* = .14, *P* = .39, *P* = .10, and *P* = .45 for LF-, HF-, AF-, and TD-SSNHL, respectively). The lymphocyte count was 1.94 ± 0.81 × 10^9^/L, 1.83 ± 0.89 × 10^9^/L, 1.78 ± 0.56 × 10^9^/L, 1.64 ± 0.68 × 10^9^/L, and 2.21 ± 0.64 × 10^9^/L in the LF-SSNHL, HF-SSNHL, AF-SSNHL, TD-SSNHL, and control groups, respectively. There was significant difference between each study group and control group in terms of lymphocyte count (all *P* \< .01). The MPV values were 10.23 ± 0.94 fL, 10.04 ± 1.43 fL, 10.77 ± 1.56 fL, 10.85 ± 1.67 fL, and 9.75 ± 1.66 fL in the LF-SSNHL, HF-SSNHL, AF-SSNHL, TD-SSNHL, and control groups, respectively. The MPVs of AF-SSNHL and TD-SSNHL patients were significantly higher than that of the control group (*P* \< .01, *P* \< .01), however, not for LF-SSNHL and HF-SSNHL (*P* = .17, *P* = .45). The PLRs were 129.43 ± 53.35, 143.40 ± 79.64, 139.49 ± 60.34, 145.62 ± 68.88, and 98.48 ± 32.68 in the LF-SSNHL, HF-SSNHL, AF-SSNHL, TD-SSNHL, and control groups, respectively. The PLRs of all audiographically distinct SSNHL patients were significantly higher than that of the control group (*P* = .03, *P* \< .01, *P* \< .01, and *P* \< .01 for LF-, HF-, AF-, and TD-SSNHL, respectively). There was no significant difference between each audiographically distinct SSNHL patients in terms of the platelet count, lymphocyte count, MPV, and PLR (all *P* \> .05).

![The difference of platelet, lymphocyte, MPV, and PLR between SSNHL groups and control group. AF-SSNHL = all-frequency SSNHL, HF-SSNHL = high-frequency SSNHL, LF-SSNHL = low-frequency SSNHL, MPV = mean platelet volume, PLR = platelet to lymphocyte ratio, SSNHL = sudden sensorineural hearing loss, TD-SSNHL = total deafness SSNHL. ∗Meant significant difference between 2 groups (*P* \< .05). The error bars indicate standard errors.](medi-96-e7877-g002){#F1}

3.2. Subgroup analysis
----------------------

All patients were divided into subgroups based on whether or not they recovered (complete, notable, and partial recovery) after 1 months of treatment with steroids, vasodilators, neurotrophic factors, vitamins B1, and hyperbaric oxygen as required. The recovery rates were 83.78%, 35.71%, 50%, and 31.25% in the LF-SSNHL, HF-SSNHL, AF-SSNHL, and TD-SSNHL groups, respectively. Table [2](#T2){ref-type="table"} details the treatment outcomes. Table [3](#T3){ref-type="table"} lists the routine blood data of all patients. Lymphocyte count, MPV, and PLR of the HF-SSNHL subgroup (all *P* \< .01) and MPV of the AF-SSNHL subgroup (*P* = .04) differed significantly from those of the other subgroups; no other parameter differed significantly among the subgroups (all *P* \> .05).

###### 

Treatment outcomes of SSNHL patients with different audiograms.
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###### 

The blood routine parameters of the recovered and unrecovered group of 4 study groups.
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4. Discussion
=============

Both the Chinese and the German guidelines^\[[@R1],[@R4]\]^ stress that SSNHL subgrouped by reference to different audiographic features may indicate that different disease mechanisms are in play and that the optimal treatments should thus vary. Recently, many studies have shown that routine blood parameters can be used both to diagnose SSNHL and to predict prognosis. Unfortunately, only a few studies have explored the relationships between SSNHLs subgrouped by audiographic data and routine blood parameters.^\[[@R16]\]^ Therefore, we determined whether significant relationships were evident between various SSNHL audiographic patterns and routine blood parameters.

Our major findings are the MPV of AF-SSNHL and TD-SSNHL, and PLR of all SSNHL patients was significantly higher than those of control group, while lymphocyte count of all audiographically distinct SSNHL patients were significantly lower than that of control group. However, no significant difference of blood parameters was observed among the 4 study groups. These indicated that although MPV and PLR may be related to SSNHL, they could not be used to classify the different type of SSNHL. Maybe we need further research to find the right biomarkers to distinguish different audiology features. Besides, the sample size we investigated was small, which may decrease the statistical power, so we need to expand the number of SSNHL patients in the further study.

Based on the therapy outcome, each SSNHL group was divided into recovery subgroup and unrecovery subgroup. Lymphocyte count, MPV, and PLR of the HF-SSNHL recovery subgroup and MPV of the AF-SSNHL recovery subgroup differed significantly from those of the unrecovery subgroups. This indicated that higher MPV and PLR, lower lymphocyte count of the HF-SSNHL, and higher MPV of the AF-SSNHL may indicate poor prognosis.

Both vascular and inflammatory factors contribute to SSNHL development.^\[[@R14]\]^ The cochlea is supplied principally by the single, terminal labyrinthine artery (a terminal division of the anterioinferior cerebellar artery: the AICA), and the inner ear is thus susceptible to alterations in circulation.^\[[@R17]\]^ SSNHL is associated with various clinical conditions including ischemic vascular disease, transient ischemic attacks, and amaurosis fugax.^\[[@R18]\]^ In patients with vascular conditions, the walls of the blood vessels may be diseased (in those with arteritis and spasms) or intravascular conditions may be in play.^\[[@R10]\]^ In addition, viral inflammation of the neural fibers and the ganglia may be important.^\[[@R19]\]^

In our data, the difference of lymphocyte count was shown significantly between audiographically distinct patients and controls; and lymphocyte count of the HF-SSNHL unrecovery subgroup was significantly higher than that of recovery subgroup. Both we and Seo et al^\[[@R14]\]^ found that the levels of lymphocytes were decreased to levels just below the normal value; Seo et al emphasized that these findings could not be considered abnormal. Furthermore, İkinciogullari et al^\[[@R20]\]^ and Masuda et al^\[[@R21]\]^ found no correlation between the lymphocyte count and the recovery rate. Nonetheless, others have suggested that a reduced lymphocyte count is associated with poorer recovery from hearing loss.^\[[@R10],[@R21],[@R22]\]^

Platelets play active roles in the pathophysiology of thrombosis, coagulation, inflammation, and vessel atherosclerosis.^\[[@R6],[@R23]\]^ The MPV is a measure of platelet activation.^\[[@R24]\]^ Larger platelets produce proteins efficiently exerting hemostatic, vasomotor, and proinflammatory functions.^\[[@R25]\]^ An elevated MPV is a risk factor for thrombotic vascular disease.^\[[@R3]\]^ Lower lymphocyte count is associated with virus inflammation; PLR is used to evaluate the extent of systemic inflammation^\[[@R5]\]^ and indicator of the extent of endothelial injury to the peripheral vascular system. Higher PLR indicates that the extent of platelet adhesion to recently damaged vessels is elevated.^\[[@R26]\]^ Both MPV and PLR are recognized as independent predictors of cardiovascular disease.^\[[@R11],[@R15],[@R27],[@R28]\]^ SSNHL has been considered to be associated with inflammation, ischemia, thrombosis, and embolisms. Recently, attention has been focused on the relationships between SSNHL and MPV and PLR.

Durmus et al^\[[@R8]\]^ found that both MPV and PLR were significantly higher in SSNHL patients who did not recover than in those who did, emphasizing the predictive utilities of these parameters in terms of prognosis. In addition, Sagit et al^\[[@R9]\]^ and Ulu et al^\[[@R13]\]^ found that the MPV was significantly higher in SSNHL group than in controls, and that vascular impairment, ischemia, and thrombosis contributed to the pathogenesis of SSNHL. However, no significant correlation between MPV and the severity of hearing loss was apparent.^\[[@R9],[@R13]\]^ Moreover, Karli et al^\[[@R3]\]^ and Ozturk et al^\[[@R29]\]^ found no significant difference between either the MPV or the platelet level when an SSNHL group and a control group were compared. Neither these clinical observations nor the results of other clinical and experimental studies support the notion that SSNHL is of vascular etiology; the MPV may be influenced by many factors including septum deviation, major depression, and insulin resistance.^\[[@R30]--[@R32]\]^ In our study, SSNHL patients were grouped by audiographic curves, the results showed that MPV of AF-SSNHL and TD-SSNHL group were significantly higher than that of control group, which may explain the conflicting data in the literature.

Moreover, Seo et al found that PLR was elevated in patients with both recurrent and nonrecurrent SSNHL, but were higher in the latter patients. Endothelial dysfunction was thought to play an important role in hearing loss physiopathology, associated with microvascular disturbance and inflammation.^\[[@R33]\]^

Recently, Salvago et al^\[[@R16]\]^ compared differences in routine blood parameters (fibrinogen level; activated partial thromboplastin time; prothrombin time; hemoglobin, white blood cell, neutrophil, and lymphocyte levels; platelet count; and hematocrit) among SSNHL patients whose audiograms differed. The lymphocyte percentage was lower and the platelet count was higher in those with down-sloping HL than in others.

Overall, we found that lymphocyte count and PLR of all audiographically distinct SSNHL, MPV of AF-SSNHL, and TD-SSNHL were significantly higher than in controls, suggesting that inflammation, platelet activity, and thrombosis play major roles in SSNHL patients. The MPV of recovering HF-SSNHL and AF-SSNHL patients were significantly lower than those of patients who did not recover. Therefore, the MPV may be useful to predict the prognosis of HF-SSNHL and TD-SSNHL patients. Besides, the lymphocyte and PLRs of recovering HF-SSNHL were significantly different from those of patients who did not recover, thus, lymphocyte and PLR may indicate the prognosis of HF-SSNHL.

5. Conclusion
=============

The most important findings are that lymphocyte count, MPV, and PLR may be relative to SSSNHL, but they could not be used to distinct SSNHL audiographically. However, platelet count did not show any relationship between SSNHL and controls, or among each SSNHL group. Furthermore, MPV and PLR in HF-SSNHL patients and MPV in AF-SSNHL patients could be used to predict the prognosis of therapy outcomes.
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